SeaStar Medical (ICU) estimates a U.S. total addressable market for its proprietary, patented Selective Cytopheretic Device in five clinical indications, subject to U.S. FDA approvals, of $25B-$33B.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICU:
- SeaStar Medical announces activation of Sentara Norfolk General as active site
- SeaStar announces two advisory firms recommended vote favor of proposals
- SeaStar Medical reaches milestone of 100th QUELIMMUNE commercial device
- Seastar Medical Faces Distribution Challenges with Self-Marketing of QUELIMMUNE
- ICU Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue